# EDGAR Filing Document

**Accession Number:** 0001993064
**File Stem:** 0001178913-26-001485
**Filing Date:** 2026-3
**Character Count:** 7133
**Document Hash:** 316a2d9432d8a8ba79f035ea9bc74566
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-001485.hdr.sgml**: 20260415

**ACCESSION NUMBER**: 0001178913-26-001485

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Zeevi Mali
- **CENTRAL INDEX KEY:** 0001993064

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35223
- **FILM NUMBER:** 26770575

**MAIL ADDRESS:**
- **STREET 1:** C/O BIOLINERX LTD.
- **STREET 2:** 2 HAMA AYAN STREET
- **CITY:** MODI IN
- **STATE:** L3
- **ZIP:** 7177871
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioLineRx Ltd.
- **CENTRAL INDEX KEY:** 0001498403
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2 HAMAAYAN STREET
- **STREET 2:** MODI-IN TECHNOLOGY PARK
- **CITY:** MODI-IN
- **PROVINCE COUNTRY:** L3
- **ZIP:** ISRAEL
- **BUSINESS PHONE:** 972-8-642-9100

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2 HAMAAYAN STREET
- **STREET 2:** MODI-IN TECHNOLOGY PARK
- **CITY:** MODI-IN
- **PROVINCE COUNTRY:** L3
- **ZIP:** ISRAEL

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioLineRX, Ltd.
- **DATE OF NAME CHANGE:** 20100805

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Zeevi Mali<br><sub>(Last) (First) (Middle)</sub><br>BIOLINERX LTD.<br>2 HAMA'AYAN STREET<br><sub>(Street)</sub><br>MODII'N,  7177871<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>BioLineRx Ltd. [ BLRX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Financial Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares, 0.1 NIS per share | 1311000 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy)<sup>(1)(2)</sup> | 2017-10-09 | 2026-10-09 | Ordinary Shares | 43800<sup>(10)</sup> | $0.264 | D |  |
| Employee Stock Option (Right to Buy)<sup>(1)(3)</sup> | 2018-02-21 | 2027-02-21 | Ordinary Shares | 126600<sup>(10)</sup> | $0.270 | D |  |
| Employee Stock Option (Right to Buy)<sup>(1)(4)</sup> | 2018-12-26 | 2027-12-26 | Ordinary Shares | 280200<sup>(10)</sup> | $0.287 | D |  |
| Employee Stock Option (Right to Buy)<sup>(1)(5)</sup> | 2020-03-25 | 2029-03-25 | Ordinary Shares | 454800<sup>(10)</sup> | $0.276 | D |  |
| Employee Stock Option (Right to Buy)<sup>(1)(6)</sup> | 2021-11-17 | 2030-11-17 | Ordinary Shares | 704400<sup>(10)</sup> | $0.150 | D |  |
| Employee Stock Option (Right to Buy)<sup>(1)(7)</sup> | 2023-03-15 | 2032-03-15 | Ordinary Shares | 1006800<sup>(10)</sup> | $0.101 | D |  |
| Employee Stock Option (Right to Buy)<sup>(1)(8)</sup> | 2024-03-21 | 2033-03-21 | Ordinary Shares | 1078800<sup>(10)</sup> | $0.045 | D |  |
| Employee Stock Option (Right to Buy)<sup>(1)(9)</sup> | 2026-11-19 | 2035-11-19 | Ordinary Shares | 13680000<sup>(10)</sup> | $0.006 | D |  |

---

### Footnotes:

(1) Options granted under the 2003 Amended and Restated Share Incentive Plan.

(2) The grant date of this grant is October 9, 2016. This option grant is fully vested as of this date.

(3) The grant date of this grant is February 21, 2017. This option grant is fully vested as of this date.

(4) The grant date of this grant is December 26, 2017. This option grant is fully vested as of this date.

(5) The grant date of this grant is March 25, 2019. This option grant is fully vested as of this date.

(6) The grant date of this grant is November 17, 2020. This option grant is fully vested as of this date.

(7) The grant date of this grant is March 15, 2022. This option grant is fully vested as of this date.

(8) The grant date of this grant is March 21, 2023. As of this date, 741,600 of the options were vested as of the date of appointment. The remaining 337,200 options will vest in 5 equal quarterly installments, subt to the Reporting Person's continued service to the Issuer as of each vesting date.

(9) The grant date of this grant is November 19, 2025. As of this date, none of the options were vested. As of the grant date 3,420,000 options have a one-year cliff and the remaining 10,260,000 options will vest in 12 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

(10) To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

**Signature:** /s/ Mali Zeevi  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**